Pilatus Biosciences Unveils Preclinical Data on CD36 Antibody PLT012 for Liver Cancer Pilatus Biosciences, a biotechnology company dedicated to developing next-generation immunometabolic therapies for cancer, has announced the publication of a pivotal preclinical study in Cancer Discovery, a leading peer-reviewed…
Guardant Health Showcases Strong Shield Test Results Across 10 Cancer Types At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), Guardant Health, Inc. , a leader in precision oncology, unveiled compelling new data from a study…
LEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics LEAP Consulting Group, a renowned boutique digital consultancy specializing in guiding national clinical diagnostic laboratories through complex, multi-phase digital transformations, has announced a strategic executive appointment that marks…
Pfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC Pfizer Inc. (NYSE: PFE) announced today significant findings from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with the standard of care (SOC) Bacillus Calmette-Guérin…
UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers, announced new data supporting its investigational intravesical…
CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research CytoAgents Inc., a clinical-stage biotechnology company at the forefront of developing therapies for immune-mediated disorders, has announced a significant milestone in its ongoing Phase 1b/2a…
Debiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research Debiopharm Research & Manufacturing S.A. (Debiopharm), a privately held, Swiss-based global biopharmaceutical company committed to advancing the treatment landscape for cancer and infectious diseases, has announced a strategic licensing…
Novocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025 Novocure, a global leader in innovative cancer treatments, has announced that it will present additional data from its pivotal Phase 3 PANOVA-3 trial of…
Zai Lab to Present Phase 1 Data on DLL3-Targeted ADC ZL-1310 at ASCO 2025 Zai Lab Limited , a leading innovative biopharmaceutical company, announced today that it will present updated clinical data from its ongoing global Phase 1a/1b study evaluating…
EditCo Bio and Promega Team Up to Advance Cell-Based Research In a pivotal move set to reshape the landscape of functional genomics and cell engineering, EditCo Bio, Inc. has announced a strategic licensing agreement with Promega Corporation. This collaboration grants…
Metro International Biotech Begins Phase 1a Trial of NAD Booster MIB-725 Metro International Biotech, LLC (MetroBiotech), a pioneering company in the development of next-generation therapies for age-associated diseases, has officially launched its first-in-human clinical trial for MIB-725, a novel investigational…
Feinstein Researchers Lead Breakthrough Study for Lupus Kidney Disease In a significant breakthrough for autoimmune disease treatment, researchers at Northwell Health’s Feinstein Institutes for Medical Research have reported encouraging results from a global Phase 3 clinical trial evaluating the use…
